Perturbation-informed signatures from crosswise integration of transcriptome and chromatin accessibility analyses predict susceptibility to candidate anticancer drugs (cisplatin validation dataset) [ATAC-seq]

Transcriptome and chromatin state of cell lines with high (Jurkat) and low (BxPC-3) sensitivity to cisplatin was acquired after 6 h 3 uM treatment with the anticancer drug, in order to validate a drug prediction pipeline based on the construction of a perturbation-informed signature. Overall design: Chromatin accessibility profile of BxPC-3 and Jurkat treated with cisplatin 3 uM for 6 h.